A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Unresectable Locally Advanced Pancreatic Carcinoma
Interventions
DEVICE

OncoSil™

The implantation of OncoSil™

Trial Locations (12)

2010

The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney

2065

Department of Medical Oncology, Royal North Shore Hospital, St Leonards

2145

The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead

2518

Corrimal Cancer Care Clinic, 20-22 Underwood St, Corrimal

3084

Institute for Breathing and Sleep -Bowen CentreAustin Health, Heidelberg

3165

Monash Cancer Centre, Melbourne

5000

Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide

Unknown

Institut Jules Bordet, Brussels

CB2 0QQ

Cambridge Cancer Trials Centre, Addenbrooke's Hospital, Cambridge

LEI 5WW

Leicester Royal Infirmary, Leicester

SE19RT

Guy's and St Thomas' NHS Foundation Trust,, London

W12 0HS

Hammersmith Hospital, London

Sponsors
All Listed Sponsors
lead

OncoSil Medical Limited

INDUSTRY

NCT03003078 - A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane | Biotech Hunter | Biotech Hunter